In San Diego on March 3, 2026, AnaptysBio, Inc. (Nasdaq: ANAB) shared progress on its plan to spin off biopharma operations and released financial figures for Q4 and full year ended on Dec. 31, 2025. AnaptysBio, a biotech firm in the clinical stage, emphasizes pioneering immunology treatments.